Galapagos N.V.
79 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
3
Ending by 2030
May 2028
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 2, 2026The maintenance fee for Ask 1 Inhibiting Pyrrolopyrimidine Derivatives (US 9,045,485) comes due Dec 2, 2026. Unpaid by Jun 2, 2027, it lapses early.
- 1 fee due Mar 3, 2027The maintenance fee for Substituted Pyrrolidines and Methods of Use (US 10,399,940) comes due Mar 3, 2027. Unpaid by Sep 3, 2027, it lapses early.
- 1 fee due Nov 12, 2027The maintenance fee for N-Sulfonylated-Pyrazolo[3,4-b]Pyridin-6-Carboxamides and Method of Use (US 10,647,717) comes due Nov 12, 2027. Unpaid by May 12, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 9 of 9
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,133,895 | Fused Pyrazine Compounds Useful for the Treatment of Degenerative and Inflammatory Diseases In force · High confidence | In force | High confidence | |
| US 7,846,932 | Methods for the Use of Pyrimidine Derivatives Which Are Antagonists of Vitronectin Receptor In force · High confidence | In force | High confidence | |
| US 8,148,369 | Fused Pyrazine Compounds Useful for the Treatment of Degenerative and Inflammatory Diseases In force · High confidence | In force | High confidence | |
| US 9,045,485 | Ask 1 Inhibiting Pyrrolopyrimidine Derivatives In force · High confidence | In force | High confidence | |
| US 9,382,254 | Novel Compounds and Pharmaceutical Compositions Thereof for the Treatment of Cystic Fibrosis. In force · High confidence | In force | High confidence | |
| US 9,867,806 | Novel Compounds and Pharmaceutical Compositions Thereof for the Treatment of Cystic Fibrosis In force · High confidence | In force | High confidence | |
| US 10,259,810 | N-SULFONYLATED PYRAZOLO[3,4-b]PYRIDIN-6-Carboxamides AND METHOD OF USE In force · High confidence | In force | High confidence | |
| US 10,647,717 | N-Sulfonylated-Pyrazolo[3,4-b]Pyridin-6-Carboxamides and Method of Use In force · High confidence | In force | High confidence | |
| US 10,399,940 | Substituted Pyrrolidines and Methods of Use In force · High confidence | In force | High confidence |
Also on record, not counted in the 9: 79 patents in force now held by others · 43 lapsed for an unpaid fee · 4 ended at full term · 1 past the fee grace period. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
3 pending · 46 abandoned · 3 no status recorded